- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07650032
Cryoablation for Monomorphic Ventricular Tachycardia (VTS) (FULCRUM-VT)
Cryoablation for Monomorphic Ventricular Tachycardia IDE Study
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
A prospective, single-arm, multi-center, open label, pre-market, clinical study designed to provide safety and efficacy data regarding the use of the Adagio System in the treatment of scar-mediated SMVT in ischemic and non-ischemic patients. Study subjects will include patients who experience recurrent SMVT and are scheduled for an endocardial VT ablation. Study subjects must have an Implantable Cardioverter Defibrillator (ICD) prior to the cryoablation procedure.
The VTS study is being initiated to collect safety and effectiveness data and support future PMA supplement marketing application.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Doug Kurschinski
- E-mail: dkurschinski@adagiomedical.com
Studie Contact Back-up
- Naam: Nabil Jubran, MS
- Telefoonnummer: 207 949 329 2494
- E-mail: njubran@adagiomedical.com
Studie Locaties
-
-
-
Montreal, Canada
- Werving
- Montreal Hear Institute
-
Contact:
- Katia Dydra, MD
-
-
Quebec
-
Montreal, Quebec, Canada, H3G 1A4
- Werving
- McGill University Health Centre (MUHC), Montreal General Hospital (MGH)
-
Contact:
- Atul Verma, MD
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85006
- Werving
- Banner University Medical Center Phoenix
-
-
California
-
Long Beach, California, Verenigde Staten, 90806
- Werving
- MemorialCare Long Beach Medical Center
-
Contact:
- Mark Lee, MD
- Telefoonnummer: (562) 933-2000
- E-mail: markyounglee@gmail.com
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02115
- Werving
- Brigham and Women's Hospital
-
-
New York
-
Staten Island, New York, Verenigde Staten, 10305
- Werving
- Northwell Health- Staten Island University Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- Hospital of University of Pennsylvania
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29403
- Werving
- Medical Center of South Carolina (MUSC)
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37232
- Werving
- Vanderbilt University Medical Center
-
-
Virginia
-
Richmond, Virginia, Verenigde Staten, 23219
- Werving
- Virginia Commonwealth University
-
Contact:
- Ajay Pillai, MD
- E-mail: ajay.pillai@vcuhealth.org
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- IC 1 Male or female ≥ 18 years
- IC 2 Patients with a clinical indication for catheter ablation due to ischemic and/or non-ischemic heart disease and recurrent symptomatic sustained scar-mediated monomorphic Ventricular Tachycardia.
IC 3 Any of the following:
- Ischemic cardiomyopapthy (ICM) patients with prior history of myocardial infarction with Q waves, focal wall motion abnormality on imaging, fixed perfusion defect correlating with coronary stenosis or prior coronary intervention, 20% ≤ LVEF < 50%.
- non-ischemic cardiomyopathy (NICM) patients with scar in a territory without coronary stenosis as evidenced by CMR imaging within the prior 90 days or intra-procedurally using EAM and PES prior to investigational device use, 20% ≤ LVEF < 50%
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- IC 4 Has received a market-released ICD prior to enrollment
- IC 5 Patient has had at least 1 documented spontaneous episode of SMVT within the previous 6 months
- IC 6 Refractory to, or intolerant of, at least one Class III AAD. (Refractory or intolerant defined as AAD failure due to recurrent VT, not tolerated/ desired due to side effects)
- IC 7 Willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study
- IC 8 Willingness and ability to give an informed consent
Exclusion Criteria:
- EC 1 Intracardiac thrombus by TTE or TEE within 48 hours prior to the procedure
- EC 2 Presence of isolated epicardial scar(s) requiring epicardial ablation identified by either preoperative CMR imaging within 90 days of procedure or intra-procedurally using EAM and PES prior to investigational device use
EC 3 VTs due to any of the following causes:
- Idiopathic VT
- Automaticity or triggered activity
- Bundle Branch Reentry (BBR)
- Any focal tachycardia (e.g., papillary, RVOT)
- Ventricular tachycardia secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause
EC 4 NICM patients only, if any of the following apply:
- Congenital condition that limits access to the left or right ventricles
- Severe aortic or mitral stenosis, severe mitral regurgitation, or severe aortic insufficiency
- Active inflammatory processes (e.g., myocarditis) within the past 120 days
- Sarcoidosis
- Hypertrophic cardiomyopathy
- Drug- or alcohol-induced cardiomyopathy
- EC 5 Any VT ablation within 4 weeks prior to enrollment
- EC 6 More than one prior (>4 weeks) VT ablation or prior surgical treatment for VT within the past 2 years
- EC 7 Cardiogenic shock, unless it is due to incessant monomorphic VT
EC 8 Any other cardiovascular conditions as described below:
- Class IV heart failure
- Aortic aneurysm
- Previous cardiac surgery or percutaneous coronary intervention within 60 days prior to index procedure
- Interatrial baffle, closure device, patch, or PFO occlusion device
- Coronary artery bypass graft (CABG) procedure within six (6) months prior to the ablation procedure
- Acute MI or unstable angina in the previous 60 days
- Mechanical mitral or aortic valve
- Cardiac myxoma
- Significant congenital heart disease
- EC 9 Acute illness or active systemic infection
- EC 10 Any previous history of cryoglobulinemia
- EC 11 History of blood clotting or bleeding disease
- EC 12 Peripheral vascular disease that precludes LV access
- EC 13 Contraindication to heparin
- EC 14 Allergy to radiographic contrast dye that cannot be medically managed prior to the ablation procedure
- EC 15 Any prior history of documented cerebral vascular accident (CVA), TIA or systemic embolism (excluding a post-operative Deep Vein Thrombosis, DVT), within 6 months prior to the ablation procedure.
- EC 16 Pregnant, or anticipated pregnancy during study follow-up
- EC 17 Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study
- EC 18 Any other condition (e.g., ARVC with extensive free wall scarring) that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, candidate for heart transplantation, patient with ventricular assist device, or terminal illness with a life expectancy less than 12 months)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: VT Cryoablation
all enrolled patients will have a ablation procedure using the vCLAS Ventricular Ablation System (VTS Catheter and Console) for SMVT
|
ablation procedure using the investigational device (vCLAS Ventricular Ablation System including VTS Catheter and Console)
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Primary Safety Endpoint - Freedom from definite or probable device or procedure related Major Adverse Events (MAEs) that occur within 7 days following the ablation procedure.
Tijdsspanne: 7 days following the ablation procedure
|
Primary Safety Endpoint is freedom from definite or probable device or procedure related Major Adverse Events (MAEs) that occur within 7 days following the ablation procedure. Events will be adjudicated by an independent Clinical Events Committee (CEC). MAEs include any of the following: • Death • Acute myocardial infarction • Cardiac perforation/pericardial tamponade • Cerebral infarct or systemic embolism • Major bleeding requiring transfusion • Acute Mitral, Tricuspid or Aortic valve damage resulting in moderate or severe regurgitation • Access site complications requiring medical or surgical intervention • Pericarditis • Heart block requiring a permanent pacemaker • Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent Clinical Events Committee (CEC) to be probably or definitely related to the Adagio System. |
7 days following the ablation procedure
|
|
Primary Efficacy Endpoint - Freedom from recurrent sustained MMVT in the absence of a new AAD or increase in dose of a pre-ablation AAD for VT management at 6 months following the ablation procedure
Tijdsspanne: 6 months after the procedure
|
Primary Efficacy Endpoint is defined as freedom from recurrent sustained MMVT in the absence of a new AAD or increase in dose of a pre-ablation AAD for VT management at 6 months following the ablation procedure, where sustained MMVT is defined as continuous MMVT for > 30 seconds (programmed monitoring zone only), or MMVT requiring appropriate ICD intervention regardless of duration.
All ICD interrogation reports will be adjudicated by an independent VT Event Committee (VTEC) to support the primary efficacy endpoint.
|
6 months after the procedure
|
|
Primary Procedural Endpoint - Percentage of non-inducibility VT targeted for ablation post-procedure
Tijdsspanne: at the end of the ablation procedure
|
Primary Procedural Endpoint is defined as non-inducibility of any VT targeted for ablation at the end of the procedure
|
at the end of the ablation procedure
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Secondary Safety Endpoint - Freedom from definite or probable device or procedure related Serious Adverse Events (SAEs) within 12 months following the ablation procedure
Tijdsspanne: 12-months post ablation procedure
|
Secondary Safety Endpoint is defined as freedom from definite or probable device or procedure related Serious Adverse Events (SAEs) within 12 months following the ablation procedure.
Events will be adjudicated by an independent Clinical Events Committee (CEC).
|
12-months post ablation procedure
|
|
Secondary Efficacy Endpoint - Freedom from VT greater than 30 seconds or appropriate ICD intervention at 12 months
Tijdsspanne: 12-months post ablation procedure
|
Secondary Efficacy Endpoint is defined as freedom from Ventricular Tachycardia lasting longer than 30 seconds or appropriate ICD intervention at 12 months
|
12-months post ablation procedure
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CS-300 Rev.H
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .